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Abstract
Leukaemia immunotherapy represents a fascinating and promising field of translational research, particularly as an
integrative approach of bone marrow transplantation. Adoptive immunotherapy by the use of donor-derived
expanded leukaemia-specific T cells has showed some kind of clinical response, but the major advance is
nowadays represented by gene manipulation of donor immune cells, so that they acquire strict specificity towards
the tumour target and potent lytic activity, followed by significant proliferation, increased survival and possibly anti-
tumour memory state. This is achieved by gene insertion of Chimeric T-cell Antigen Receptors (CARs), which are
artificial molecules containing antibody-derived fragments (to bind the specific target), joined with potent
signalling T-Cell Receptor (TCR)-derived domains that activate the manipulated cells. This review will discuss the
main application of this approach particularly focusing on the paediatric setting, raising advantages and
disadvantages and discussing relevant perspectives of use in the nearest future.
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Introduction
Chimeric T-cell Antigen Receptors (CARs) are a fasci-
nating bio-technologic step in the field of immunother-
apy to orient the activity of immune cells towards
specific molecular targets expressed on the cell surface
of various tumours, including haematological malignan-
cies. CARs are artificial T-cell receptors constituted by
an antigen-recognizing extracellular domain derived
from an antibody molecule linked to a T-cell triggering
domain [1-4]. CARs are generated by joining the heavy
and light chain variable regions of a monoclonal anti-
body, expressed as a single-chain Fragment variable
(scFv) molecule, to an intracellular signalling domain,
usually the zeta-chain of the TCR/CD3 complex or the
gamma-chain from the Fc-epsilon-RI receptor Figure 1.
T lymphocytes genetically engineered to express CARs
exhibit specific lysis towards tumour cells and cytokine
secretion upon exposure to the respective target antigen.
The CAR-mediated effector function may produce sus-
tained tumour cell lysis more likely than humoral
immune responses alone, based on the use of monoclo-
nal antibodies. The perforin/granzyme killing mechan-
ism may be effective against cells that are relatively
resistant to antibody and complement, while cytokine
secretion recruits additional components of the immune
system, amplifying and prolonging the anti-tumour
immune response. Moreover, effector T cells display
efficient tumour penetration and homing capabilities
[1-4].
The CAR approach permits to overcome the major
limitations associated with the use of a “classical” TCR
transgenic molecule. In fact, target recognition by CAR
is non-MHC restricted and independent of antigen pro-
cessing, therefore allowing its use in patients with differ-
ent haplotypes and bypassing tumour escape due to
MHC-molecules down-regulation. In addition, CARs
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like carbohydrates and glycolipids, and there is no risk
to trigger unpredictable and potentially harmful specifi-
cities, as it may happen with transduced TCR, that
could form hybrids with the endogenous TCR [1-4].
Different CARs have been generated so far [2,3,5],
against a wide range of surface molecules expressed by
many solid tumours and haematological malignancies.
The efficacy of this strategy has been recently proved by
a phase I clinical trial in patients with neuroblastoma. In
this study, the authors generated a CAR directed to the
diasialoganglioside G(D2a), a tumour-associated antigen
expressed by human neuroblastoma cells. They demon-
strated that Epstein-Barr virus (EBV)-specific cytotoxic
T lymphocytes (CTLs) engineered to express the G(D2a)
specific-CAR survive longer than T cells activated by the
CD3-specific antibody OKT3 expressing the same CAR,
but lacking virus specificity. Moreover, infusion of these
genetically modified cells was associated with tumour
regression or necrosis in half of the subjects tested [6].
How to build a Chimeric Artificial Receptor
The ectodomain represents the extracellular part of the
artificial T-cell receptor. It is generally composed by a
signal peptide, an antigen recognition region and a
spacer sequence. The signal peptide directs the nascent
protein into the endoplasmic reticulum. This is essential
if the receptor needs to be glycosylated and anchored in
the cell membrane leading to the CAR expression. The
antigen recognition domain is usually a scFv, obtained
by the fusion of the variable regions of the heavy (VH)
and light (VL) chains of Immunoglobulins (Igs), joined
t o g e t h e rw i t has h o r tl i n k e r .T h el a t t e ri su s u a l l yas e r -
ine-glycine rich motif, whose flexibility assures a high
mobility capacity to the molecule Figure 1. This chi-
meric domain retains the specificity of the original Ig,
Figure 1 the structure of a CAR.
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duction of a linker peptide. The traditional method to
obtain the scFv was based on the use of mouse hybri-
doma producing the specific antibody necessary to have
the variable fragments of the VL and VH chains [7]. A
new approach, more suitable int h i sc o n t e s t ,i sr e p r e -
sented by the technology of synthetic DNA. To generate
the scFv binding domain by a “synthetic DNA “
approach, guidelines published by Rydzanicz et al. can
be adopted [8]. As a DNA template for the VH and VL
fragment it is possible to use a humanized antibody
published sequence. Once the final scFv sequence con-
taining the leader sequence and the flexible linker is
found and projected, it is possible to proceed with the
synthetic DNA generation. The Rydzanicz et al. method
is based on dividing the putative sequence into different
overlapping oligonucleotides. To generate specific and
functional overlapping oligonucleotides, they created a
free online software “Assembly PCR oligo maker” http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC1160141/. This
software calculates the overlapping oligonucleotides fol-
lowing the putative sequence with specific values of T
melting (Tm), thus avoiding non-specific and random
annealing possibilities. The overlapping oligonucleotides
are then joined together exploiting a basic PCR reaction
in order to generate the putative template. A second
reaction of PCR is then needed to amplify the new syn-
thetic template using flanking primers Figure 2.
Clinical application in haematology
Haematological malignancies represent optimal targets
for the exploitation of CARs, because of the bright
expression of specific antigens on the surface of tumour
cells. Previous studies from our group demonstrated
that B-lineage acute lymphoblastic leukaemia can be
efficiently targeted by a CAR directed against the CD19
antigen [9,10]. We have shown that, after transduction
with anti-CD19 CARs, cytokine induced killer (CIK)
cells, a peculiar population of effector cells, acquire
potent anti-leukemic activity in terms of cytotoxicity,
proliferation and release of immunostimulatory cyto-
kines upon specific antigen recognition. In line with
these observations, an European consortium http://www.
childhope.eu/contents.php have been developed, funded
in the contest of a STREP (6
th framework) to target
high-risk B-ALL in molecular relapse after
Figure 2 the Synthetic DNA Technology applied to the
anti-CD23.CAR.
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expressing EBV-CTLs. The preclinical in vivo data, tar-
geting primary patient-derived high-risk B-ALL [11],
demonstrated the efficacy of such an approach and
paved the way, for the first time in the field of paediatric
leukaemia, for the design of a phase I clinical trial. In
this trial paediatric patients, who received allogeneic
transplantation, will be infused with donor-derived anti-
CD19. CAR-expressing EBV-CTLs, as soon as the reap-
pearance of the disease is detected by early Minimal
Residual Disease (MRD) analysis. A single injection will
be performed after a lympho-depletion schedule by flu-
darabine and discontinuation of imunosuppression.
Similarly, four other main groups are developing CAR-
based strategies for targeting B-origin leukaemia-lym-
phoma neoplasm, by using CD19 as the selected target.
Indeed, the MK Brenner’s group has recently published
interesting even though preliminary observations con-
cerning the in vivo superior effect of second generation
CARs containing, beyond the zeta-chain, a costimulatory
molecule, specifically the CD28 domain. Patients with B
cell lymphomas were infused with two different autolo-
gous T-cell products expressing CARs with the same
specificity for the CD19 antigen: one CAR encoded both
the costimulatory CD28 and the zeta endodomains,
while the other presented the zeta endodomain alone.
CAR-expressing T cells containing the CD28 endodo-
main showed markedly enhanced growth and persis-
tence compared with CAR-expressing T cells encoding
the zeta endodomain alone [12]. Similar and promising
results have been obtained in humans by the CH June’s
and SA Rosenberg’s groups, targeting the CD19 antigen
in lymphoma patients by using gene-modified autolo-
gous T cells [13,14]. Both groups observed and mea-
s u r e dl o n g - l a s t i n ge r a d i c a t i o ne v e ni nc a s eo f
disseminated tumours, either by single or multiple injec-
tions of anti-CD19. CAR-expressing T cells. Lastly, the
LJ Cooper’s group has recently proposed a clinical-grade
non-viral method to transduce T cells with the anti-
C D 1 9 .C A R :t h e“Sleeping Beauty” transposon/transpo-
sase system. This innovative method is based on the
nucleofection/electroporation of plasmidic DNA, allow-
ing cells to be stably transduced in their nucleus and
avoiding the use of viral vectors [15].
Other potential optimal targets of CAR-gene transfer
are represented by Acute Myeloid Leukaemia (AML)
and Chronic Lymphocytic Leukaemia (B-CLL), because
of the selective expression of tumour-associated surface
antigens, possible targets of CAR recognition.
Immunotoxin-based therapy against CD33
+ myeloid
leukaemia using gemtuzumab ozogamicin (Mylotarg)
[16] had some success, albeit associated with liver
(Veno-Occlusive Disease) and haematological toxicity in
a significant number of patients [16]. With the
exception of acute promyelocytic leukaemia, the curative
potential of Mylotarg as a single agent is still limited
[16]. Immunotherapy with T cells using unmanipulated
donor lymphocyte infusion (DLI) for the treatment of
leukaemia recurrence in Haematological Stem Cells
Transplantation (HSCT) recipients has shown some
positive results in AML, but the use of DLI carries a sig-
nificant risk of inducing Graft versus Host Disease
(GvHD) [17]. The identification of leukaemia-associated
antigens eliciting T-cell responses in vitro, has been suc-
cessful for AML [18]. However, the generation of leu-
kaemia-specific cytotoxic T cells against AML-associated
antigens has been hampered by several factors: the poor
immunogenicity of blasts lacking costimulatory mole-
cules and the low frequency of T-cell precursors in anti-
gen-naïve marrow donors or in patients anergized by
their own leukaemia. An attractive strategy to overcome
these limitations may be represented by the use of
human T cells that bear CARs specific for CD33 mole-
cule. In line with these considerations, we have recently
published an in vitro model that strongly demonstrates
the efficiency of anti-CD33. CARs towards myeloid cell
lines and primary blasts, by using gene modified CIK
cells [19]. The infusion of CIK cells in patients with
AML relapsing after HSCT is well tolerated, but limited
clinical responses were observed [20]. To improve their
effector functions against AML, CIK cells were geneti-
cally modified with CARs specific for the CD33 myeloid
antigen by using SFG-retroviral vectors encoding for
anti-CD33-zeta and anti-CD33-CD28-OX40-zeta chi-
meric receptors. Anti-CD33. CARs modified CIK cells
acquired potent cytotoxicity (up to 80% lysis) against
various AML targets, also confirmed in long-term killing
experiments. Moreover, a relevant CD33-specific prolif-
eration was measured, accompanied by the release of
high levels of immunostimulatory cytokines. The pre-
sence of CD28-OX40 in CAR endodomain was asso-
ciated with a significant amelioration of the anti-
leukaemia activity of modified CIK cells. Representative
data showing anti-CD33 and anti CD19 CAR-mediated
killing and immunostimolatory capacities are shown in
Figure 3. Importantly, even though a certain toxicity
against normal haematopoietic CD34
+ progenitor cells
was measured, their residual haematopoietic activity was
anyway preserved [19], thus opening the way for possi-
ble clinical applications of the anti-CD33. CAR strategy.
In vivo experiments are currently ongoing in order to
measure the safety and efficacy profile of anti-CD33.
CAR-expressing cells in an immunodeficient mouse
model.
Similarly to ALL and AML, B-CLL may represent as
well an interesting target for CAR strategy. B-CLL cells
expressing CD19 and CD20dim are suitable to be tar-
geted with T cells redirected against these pan-B
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Page 4 of 9Figure 3 CARs activity towards myeloid (CD33
+) and lymphoid (CD19
+) acute leukaemias. The figures show different tests adopted to
measure the efficacy of transduced T cells. The panels on the left side describe the effect on AML cells, whilst the right panels on ALL cells. The
test shown are, starting from the top: 1) short term cytotoxicity, by classic Chromium release assay; 2) long-term cytotoxicity, measured as
recovery of leukaemia cells after 1-week of co-incubation with effectors cells; 3) cytokine release, by Elisa tests; 4) proliferation index, measured as
ration versus the basal number by thymidine incorporation assay. All the tests are described in details in reference no. 19.
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these self tissue-restricted B-cell antigens [12-15]. How-
ever, B-CLL hypo-gammaglobulinemia is present in
approximately 8% of patients at diagnosis and progres-
sively increases along the natural history of the disease.
Thus, targeting pan-B markers can potentially further
compromised the immunity of these patients. A more
selective self-antigen in B-CLL that can be more suitable
is the CD23 molecule, because of its higher expression
on B-CLL cells as compared to normal B lymphocytes
[21]. CD23 is the low-affinity receptor for IgE and its
expression and function is physiologically restricted to
IgE-secreting B lymphocytes, mast cells, platelets and
dendritic cells. Lumiliximab (L-mab), a macaque-human
chimeric anti-CD23 monoclonal antibody, has been
used in a Phase I-II study, to test its safety, efficacy, and
pharmacokinetics. In the last study 31 patients received
either 375 mg/m(2) (n = 3) or 500 mg/m(2) (n = 28) of
L-mab in combination with Fludarabine, Cyclophospha-
mide and Rituximab (FCR) for 6 cycles [22]. The overall
response rate was 65%, with 52% of patients achieving a
complete response (CR). Study-related adverse events
were mild and evidence of clinical activity consisted of
reductions in absolute lymphocyte counts and lympho-
nodes size. T cells redirected against CD23 through a
specific CAR may further improve these results. In line
with these observations, we have recently published an
in vitro and in vivo model that corroborates this hypoth-
esis [23]. We cloned and expressed in T lymphocytes a
novel CAR targeting the CD23 antigen. Anti-CD23.
CAR-expressing T cells showed specific cytotoxic activ-
ity against CD23
+ tumour cell lines (average lysis 42%)
and primary CD23
+ CLL cells (average lysis 58%). This
effect was obtained without a significant toxicity against
normal B lymphocytes, in contrast to CARs targeting
CD19 or CD20 antigens, which are also physiologically
expressed by normal B lymphocytes. Moreover, autolo-
gous CLL-derived-CD23. CAR-expressing T cells signifi-
cantly released inflammatory cytokines and IL-2 was
also produced to sustain the CD23-driven proliferation
of such modified T cells. Redirected T cells were also
effective in vivo in a CLL Rag2(-/-)gc(-/-) xenograft
mouse model [24]. Indeed, the infusion of anti-CD23.
CAR-expressing T cells resulted in a significant delay in
the growth of the CLL-derived cell line (MEC-1). These
data suggest that anti-CD23. CAR-expressing T cells
represent a selective immunotherapy approach for the
elimination of CD23
+ leukaemia cells in patients affected
by B-CLL.
Despite the promising results obtained so far, CAR
strategy might be further optimized. Several reports
indicate that the addition of costimulatory molecules
(such as CD28, ICOS, CD134 or CD137), either as sin-
gle domain or as multiple combinations, to the
signalling CAR endodomain induces a higher rate of
proliferation, higher levels of IL-2 secretion and pro-
longed effector cells survival with a subsequent better
activity in vivo [25]. An additional approach to amelio-
rate CAR-mediated effector functions might be the inac-
tivation of inhibitory molecules. These inhibitory ligands
are expressed on various tumour cells and are associated
with functional impairment of extensively in vitro stimu-
lated T cells: their blockade can accelerate tumour era-
dication [26]. A different strategy to guarantee an
improved and totally physiological activation of T cells
can be achieved exploiting an activated native TCR,
such as a viral targeting TCR, in addition to the CAR
specificity (the so-called “dual-specific” T cells) [6]. In
this condition, the activation of the natural TCR should
provide a powerful stimulus, maintaining at the same
time the killing capacity, the proliferative activity and
the durable persistence of the CAR-related functions.
Indeed, MK Brenner’s group has recently adopted EBV-
specific CTLs, transducing them with a CAR targeting
the G(D2a) antigen expressed by neuroblastoma cells.
Such manipulated cells preserved an intact activity
towards the viral target and also killed the neuroblas-
toma cells through the anti-G(D2a). CAR. As described
above, this strategy has been proved to be feasible and
efficient in a recent phase I clinical trial [6].
Alternatively to the use of EBV-CTLs, other T-cell
subsets have shown some potential for future adoptive
immunotherapeutic approaches. In line with previous
considerations, there is enough evidence to support the
in vivo use of chimeric EBV-CTLs in paediatric
relapsed/refractory ALL patients, as planned in a Phase
I trial in the context of the “Childhope” STREP-funded
network. However, additional preclinical experiments
are crucial to compare the respective anti-tumour effi-
cacy of chimeric EBV-CTLs, chimeric CIK cells and chi-
meric gamma9delta2 T cells (GDT) for future clinical
applications. CIK cells are T cells with natural killer cell
phenotype and function, enriched in CD3+CD56+ cells
[19], that can be easily expanded from human peripheral
blood mononuclear cells up to 200-1000 fold in 14-21
days of culture after an initial priming with IFN-gamma
and OKT-3 followed by repeated stimulation with high-
doses of IL-2 [20]. It has been demonstrated that CIK
cells can lyse a broad array of tumour targets in a non-
MHC-restricted manner and display an in vivo potent
anti-tumour activity, while having reduced propensity to
induce GvHD [27]. Phase I studies have been performed
with CIK cells in various contexts, where no toxicity
was observed and several partial responses were
detected [20-27]. Similarly, human peripheral GDT T
cells are a proved alternative to conventional CTLs. The
vast majority of peripheral blood GDT cells, that repre-
sent 0.5 to 5.0% of whole peripheral blood T cells in
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variable regions called Vgamma9 and Vdelta2. Beside
their known anti-infectious activity -in particular follow-
ing allogeneic HSCT- it was shown that GDT cells are
able to kill a wide variety of tumour cell lines from very
diverse origins [28]. GDT cells can be selectively
expanded in vivo or in vitro in the presence of aminobi-
sphosphonates without prior antigen priming [29].
Recently, it has been shown that human GDT cells can
be expanded in the presence of zoledronate and effi-
ciently transduced with a retroviral vector encoding a
CD19-specific CAR. Transduced GDT cells powerfully
recognised and lysed antigen-expressing tumour cell tar-
gets [30]. To unravel such an important issue, we have
recently published a comparison, in an in vitro model,
of the above mentioned populations as putative effectors
of CAR-mediated immunotherapy [31]. Our results indi-
cate that the expression of an anti-CD33-zeta chimeric
receptor potently and similarly increases the antileukae-
mic functions of different effector T-cell subtypes. This
underlines the impossibility to identify a more potent T-
cell population through an in vitro analysis. Moreover,
these results are consistent with recent observations that
have emerged from clinical trials with CAR-modified T
cells, suggesting the need to perform such type of stu-
dies in the human setting.
An important consideration for the clinical applic-
ability of CAR strategy is represented by the safety
issues concerning the use of integrating vector for
gene transfer, as well as the potential reactivity of
CAR-transduced cells against host-normal cells expres-
sing the target antigen. Furthermore, the potential
hazards associated with the use of CAR containing
costimulatory or growth-promoting molecules that
may improve the survival and the proliferation of
manipulated T cells need to be investigated [1-4].
These limitations can be overcome by introducing sui-
cide genes that constitute a back-up control to be used
in case of unexpected reactivity of transduced cells
[32]. Several suicide gene strategies have been
described so far. The most described approach has
been based on the thymidine kinase gene of the
Herpes Simplex virus (HSV-TK). Expression of the
HSV-TK gene by transduced T cells renders them sus-
ceptible to the effects of gancyclovir (GCV). Several
groups have reported that transduced T cells retained
their anti-leukaemia effect, including long-lasting
remissions in some patients [33]. However, HSV-TK is
highly immunogenic in humans. The most recently
described strategy is the inducible Casp9 suicide sys-
tem, which is based on a fusion protein constituted by
human caspase 9 and the modified human FK506
binding protein (FKBP), that allows conditional dimeri-
sation triggered by a chemical inducer of dimerisation
(CID) [34]. Other suicide genes that have been studied
include the human CD20, which is targeted by the
monoclonal antibody Rituximab [35], and a mutant
human thymidylate kinase (mTMPK), which renders
transduced cells susceptible to zidovudine (AZT) [36].
A fundamental step to identify the optimal suicide
approach for clinical intervention requires a direct
comparison of all these systems. Our preliminary
results (unpublished data)c o n f i r mas u b s t a n t i a l
equivalence of the HSV-TK and Casp9-CID systems,
having the latter the double advantage of not being
immunogenic and exerting its activity in a more rapid
timeframe.
Conclusions
In conclusion, CARs represent a potential useful tool to
fight various resistant forms of leukaemia. As recently
discussed by Helen Heslop [37], more than 10 clinical
trials using second or third-generation CARs are cur-
rently present on http://ClinicalTrials.gov, and there is
some encouraging preliminary evidence of their clinical
efficacy. On the other side, two serious adverse events
have been reported. The first event [38] occurred in a
patient with largely metastatic colon cancer who was
infused with more than 10
10 T cells expressing a third-
generation CAR targeting HER2, after being pre-treated
with an intensive lymphodepletion regimen. The patient
rapidly presented pulmonary toxicity within few min-
utes, followed by cardiac arrest and finally died few days
later. The investigators concluded that the toxicity was
due to targeting of low levels of HER2 on pulmonary
endothelium by transgenic T cells. In the second clinical
case, Brentjens and colleagues described a patient with
bulky CLL and extensive previous chemotherapy treat-
ment who received autologous T cells expressing a sec-
ond generation anti-CD19. CAR at a dose of 3 × 10
7
cells/kg after being lymphodepleted with cyclophospha-
mide [39]. This patient suddenly developed fever, hypo-
tension, and dyspnea few hours after infusion, with
rapid fatal progression. An autopsy did not reveal a
clear cause of death. It was concluded that low grade
sepsis was the most likely triggering factor in this heav-
ily pre-treated patient, but it was also hypothesized that
a cyclophosphamide-induced “cytokine storm” may have
potently augmented the in vivo activation process of
modified T cells.
All these aspects have been currently widely consid-
ered and discussed by many researchers and regula-
tory experts in the field of cell and gene therapy.
Different schedules of administration (dose-escala-
tion) with a reduced cell numbers or fractionated
doses, together with a betterc h o i c eo fp r e - a d m i n i s -
tration lympho-depletive regimens, in patients with
minimal residual disease, would probably diminish
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Withal, the use of CARs containing suicide-gene
switch-off mechanisms could be helpful in case of off-
target side events [4,40].
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